DO-BO

How has virtual become reality in Market Access, Glib Kutepov?

What role will AI & VR transformations play in the future? Tune in to this fascinating episode of the Market Access Podcast to hear as our special guest, Glib Kutepov, CEO and founder of Modulate, shares his expertise. 

Glib uncovers the potential of generative AI and neural networks in revolutionizing market access strategies and highlights the challenges and solutions around data privacy as well as the integration of private layers to protect sensitive information. He also touches on the role of VR in empathizing with patients’ experiences, adding a deeply human element to the data-driven world of market access. This episode will not only provide a deeper understanding for the technology, but also tools of practical ways to implement it.

AI and VR could change the data driven health care in the future, as it can benefit the strategic work as well as assist in ensuring a better understanding for the patients’ experiences. Whether you’re a healthcare professional, market access manager, or tech enthusiast, this conversation offers a glimpse into a future where technology enhances our approach to healthcare on multiple levels.

Related

By the time most health economists get pulled in, the recipe is already set. In this episode of MAP — the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist […]

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]